Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL Hideki Fujino*, Iwao Yamada, Shimada Shimada, Masaru Hirano, Yoshihiko Tsunenari and Junji Kojima Tokyo New Drug Research Laboratories I, Kowa Company Ltd., Tokyo, Japan SUMMARY An in vitro study was carried out in order to examine the metabolic basis of the . Metabolic inhibition of statins was noted in the presence of gemfibrozil. However, increase in the unchanged form was fairly small for pitavastatin, compared with other statins. Several CYP enzymes were shown to be principally responsible for the metabolism of gemfibrozil in contrast to other fibrates. In the presence of gemfibrozil, a focal point was obtained in Dixon plots, demonstrating that there was inhibition of CYP2C8-, CYP2C9- and CYP3A4-mediated metabolism. We propose that the increase of plasma concentration caused by co-administration of gemfibrozil and statins is at least partially due to CYP-mediated inhibition. KEY WORDS pitavastatin, cerivastatin, gemfibrozil, HMG-CoA reductase inhibitor, fibrates * Author for correspondence: Hideki Fujino, Ph.D. Tokyo New Drug Research Laboratories I, Kowa Company Ltd. 2-17-43 Noguchicho, Higashimurayama Tokyo 189-0022, Japan e-mail: h-fujino@kowa.co.jp © F r e u n d P u b l i s h i n g H o u s e Ltd., 2 0 0 3 Interaction Between Fibrcites and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Metabolism and Drug Interactions de Gruyter

INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

Download PDF
16 pages

Loading next page...
 
/lp/de-gruyter/interaction-between-fibrates-and-statins-metabolic-interactions-with-CXQj76OXFQ

References (11)

Publisher
de Gruyter
Copyright
Copyright © 2003 by the
ISSN
2191-0162
eISSN
2191-0162
DOI
10.1515/DMDI.2003.19.3.161
Publisher site
See Article on Publisher Site

Abstract

Hideki Fujino*, Iwao Yamada, Shimada Shimada, Masaru Hirano, Yoshihiko Tsunenari and Junji Kojima Tokyo New Drug Research Laboratories I, Kowa Company Ltd., Tokyo, Japan SUMMARY An in vitro study was carried out in order to examine the metabolic basis of the . Metabolic inhibition of statins was noted in the presence of gemfibrozil. However, increase in the unchanged form was fairly small for pitavastatin, compared with other statins. Several CYP enzymes were shown to be principally responsible for the metabolism of gemfibrozil in contrast to other fibrates. In the presence of gemfibrozil, a focal point was obtained in Dixon plots, demonstrating that there was inhibition of CYP2C8-, CYP2C9- and CYP3A4-mediated metabolism. We propose that the increase of plasma concentration caused by co-administration of gemfibrozil and statins is at least partially due to CYP-mediated inhibition. KEY WORDS pitavastatin, cerivastatin, gemfibrozil, HMG-CoA reductase inhibitor, fibrates * Author for correspondence: Hideki Fujino, Ph.D. Tokyo New Drug Research Laboratories I, Kowa Company Ltd. 2-17-43 Noguchicho, Higashimurayama Tokyo 189-0022, Japan e-mail: h-fujino@kowa.co.jp © F r e u n d P u b l i s h i n g H o u s e Ltd., 2 0 0 3 Interaction Between Fibrcites and

Journal

Drug Metabolism and Drug Interactions – de Gruyter

Published: Mar 1, 2003

There are no references for this article.